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Abstract
Background: The effect of genetic factors, apart from 5,10-methylenetetrahydrofolate reductase (MTHFR) polymorphisms,
on elevated plasma homocysteine levels and increasing ischemic stroke risk have not been fully elucidated. We conducted a
comprehensive analysis of 25 genes involved in homocysteine metabolism to investigate association of common variants
within these genes with ischemic stroke risk.
Methodology/Principal Findings: The study was done in two stages. In the initial study, SNP and haplotype-based
association analyses were performed using 147 tagging Single Nucleotide Polymorphisms (SNPs) in 360 stroke patients and
354 non-stroke controls of Singaporean Chinese ethnicity. Joint association analysis of significant SNPs was then performed
to assess the cumulative effect of these variants on ischemic stroke risk. In the replication study, 8 SNPs were selected for
validation in an independent set of 420 matched case-control pairs of Singaporean Chinese ethnicity. SNP analysis from the
initial study suggested 3 risk variants in the MTRR, SHMT1 and TCN2 genes which were moderately associated with ischemic
stroke risk, independent of known stroke risk factors. Although the replication study failed to support single-SNP
associations observed in the initial study, joint association analysis of the 3 variants in combined initial and replication
samples revealed a trend of elevated risk with an increased number of risk alleles (Joint Ptrend=1.2610
26).
Conclusions: Our study did not find direct evidence of associations between any single polymorphisms of homocysteine
metabolic pathway genes and ischemic stroke, but suggests that the cumulative effect of several small to moderate risk
variants from genes involved in homocysteine metabolism may jointly confer a significant impact on ischemic stroke risk.
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Introduction
Ischemic stroke is a complex multifactorial disease influenced by
several genetic and environmental factors [1–2]. Epidemiological
studies have identified several clinical risk factors that are highly
correlated with stroke risk; these in turn implicate various bio-
logical pathways, including the homocysteine metabolism[3], lipid
metabolism[4], renin-angiotensin-aldosterone system[5–6], hae-
mostatic system[6], phosphodiesterase 4D[7] and leukotriene
pathways[8], in stroke pathophysiology. Moderate elevation of
plasma homocysteine levels has been identified as a major risk
factor for vascular diseases, including stroke[3]. Data from cohort
and case-control studies suggest a positive, and dose-dependent
association between the serum concentration of total homocysteine
and the risk of stroke, which is independent of other vascular risk
factors[9]. In meta-analyses of large cohorts, it has been estimated
that for every rise in plasma homocysteine level of 5 umol/L, the
risk for cerebrovascular disease increases by 50% (95% CI, 30-
90%) while plasma homocysteine levels above the 95
th percentile
was associated with an odds ratio (OR) of 3.97 (95% CI, 3.07 to
5.12) for cerebrovascular disease[10–11].
Mutations in genes of the homocysteine metabolic pathway may
confer an increased risk for ischemic stroke as a consequence of
elevated plasma homocysteine levels. A common polymorphism
(C677T) in the gene encoding 5,10-methylenetetrahydrofolate
reductase (MTHFR), a critical enzyme in homocysteine metabo-
lism, has been reported by several studies to be associated with
both elevated plasma homocysteine levels and increased stroke
risk[12–13]. A recent meta-analysis further confirmed the
association with variation in plasma homocysteine levels (weighted
mean difference in homocysteine levels of 1.93 mmol/L for TT vs
CC) and increased risk of stroke (OR 1.26 for TT vs CC)[14].
However, the C677T polymorphism alone accounts for less than
10% of the variance in plasma homocysteine levels[3].
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24757Several polymorphisms in other homocysteine regulatory genes
have also been investigated, but their effects on plasma homo-
cysteine remain unclear. The A2756G polymorphism in 5-
methyltetrahydrofolate-homocysteine methyltransferase (MTR)w a s
identified to be associated with decreased plasma homocysteine
levels, but only in some populations[15–16]. The first genome-wide
linkage analysis of plasma homocysteine levels, performed in a
Spanish population, found that the nicotinamide N-methyltrans-
ferase (NNMT) gene was the most significant genetic determinant of
plasma homocysteine[17]. A second genome wide linkage study,
performed in non-Hispanic whites and blacks, identified several
genomic regions (non-Hispanic whites: chromosomes 6q26 and
18q21, blacks: chromosome 2q32, 7p15, 8q24, 18q21, and 20p12)
showinglinkagewith plasmahomocysteine levels[18].However, the
results from these two genome-wide linkage studies are largely
inconsistent. Furthermore, the roles of these polymorphisms and
linkage loci in stroke risk have not been evaluated.
Postulating that there are additional genetic risk variants other
than the MTHFR C677T variant that elevate plasma homocys-
teine levels and thus increase risk for ischemic stroke, we
performed a comprehensive genetic association study of the
homocysteine metabolic pathway by investigating 25 homocyste-
ine metabolic pathway genes in well-characterized ischemic stroke
cases and matched controls of Singaporean Chinese ethnicity.
This is the first comprehensive study to be performed in a Chinese
population, which has been underrepresented in the earlier linkage
and association studies.
Results
Initial Study
We analyzed 147 tagging SNPs using the Cochrane-Armitage
trend tests to obtain ORs and 95% Confidence Intervals (CI) (Table
S1). After an adjustment for other known non-genetic risk factors
(vascular risk factors, age and gender), rs16879248 in MTRR (5-
methyltetra-hydrofolate-homocysteine methyltransferase reduc-
tase), rs11868708 in SHMT1 (serine hydroxymethyl-transferase 1)
and rs11703570 in TCN2 (transcobalamin II), show suggestive
association with ischemic stroke risk (P,0.05) (Table 2). While
rs16879248showedaprotectiveeffect(OR=0.67),rs11868708and
rs11703570 were associated with increased risk for ischemic stroke
(OR=1.46 and 1.51 respectively). The associations at all 3 SNPs
appear to fit an additive or dominant model (Table S4).
In addition to single SNP-based association analysis, we
performed haplotype analysis of 19 candidate genes. As shown
in Table 3, results from the haplotype analysis were largely
consistent with the single SNP analysis for SHMT1 and TCN2.W e
also analyzed pair-wise interaction among the 3 associated SNPs
as well as all the 147 tagging SNPs, but no evidence of interaction
was found.
Finally, given the moderate effects observed in single SNP
analysis, we evaluated the joint effect of the 3 genetic risk variants
(rs16879248, rs11868708 and rs1173570) that were significant in
thesingleSNPanalysis.AsshowninTable4,the3 variantsappeared
to show a strong cumulative association with ischemic stroke risk.
The increased number of the risk alleles was significantly associated
with an increased risk of ischemic stroke; the joint effect was
independent of aforementioned non-genetic risk factors
(Ptrend=2.0610
27) and remained significant after correction for
model selection bias (corrected Ptrend=0.013, 5000 permutations).
Replication Study
In the replication study, the allelic ORs of all the 3 tagging SNPs
and the haplotype in SHMT1 and TCN2 were observed to be in
the same direction of effect as the initial study (Table 2 & 3),
although these results did not reach statistical significance.
However, the joint association analysis of the 3 variants in the
replication study showed a similar cumulative association with
ischemic stroke. Although not statistically significant, the trend of
elevated stroke risk with an increased number of risk alleles was
largely consistent in both studies, with exception of the group with
4 total risk alleles (Table 4). This may be attributed to the small size
of the subgroups with different numbers of risk alleles. When the
initial and replication samples were combined, a clear trend of
elevated ORs with increased number of risk alleles was observed
and the joint effect was independent of the aforementioned non-
genetic risk factors (Combined Ptrend=1.2610
26).
Discussion
Stroke is a multifactorial and polygenic disorder with some well-
identified environment factors, but the genetic risk factors for
stroke remain to be elucidated. In the initial study, we performed a
comprehensive analysis of 25 candidate genes involved in the
homocysteine metabolic pathway in a well-characterized group of
ethnic Chinese with ischemic stroke. We analyzed controls
matched for ethnicity and geographic location, thus reducing the
possible effects of population stratification on the association results.
Moreover, cases and controls were found to be well-matched and of
Chinese ancestry in a principle component analysis with 147
tagging SNPs (Figure S1). The differences between cases and controls
in terms of age, smoking, gender, hypertension and diabetes reflect
the established associations of these factors with ischemic stroke; the
prevalence of smoking, hypertension and diabetes in controls was
similar to the Singapore general population according to the
National Health Survey 2004 (NHS 2004). To our knowledge, this
is the most comprehensive genetic association study to date of the
homocysteine metabolic pathway genes in subjects of Chinese
ethnicity with ischemic stroke.
Our initial study provided suggestive association evidence for 3
candidate genes whose genetic effect are likely independent of
other common non-genetic risk factors such as age, gender,
smoking, hypertension, diabetes and hyperlipidemia. In addition,
although the association evidence for the 3 genetic risk variants are
moderate and did not survive correction for multiple testing, the
joint effect of these variants is strong and the association remained
significant after correction for model selection bias.
We did not find a significant association between MTHFR
C677T and ischemic stroke risk in our initial samples. MTHFR
C677T has been shown to be associated with ischemic stroke risk
in Chinese population by a multi-center case-control study, but the
genetic effect was found to be relatively weak (OR=1.27, TT
versus CC homozygotes) [19]. We estimate that our study had
only 21% power to detect this weak association.
None of the single SNPs or haplotypes showed statistically
significant association in the replication study. With the current
sample size of the replication study, we had limited statistical
power to validate the small to moderate effects of single SNPs.
Moreover, the case and control subjects were 5–8 years younger
compared to the initial study, and the inclusion of young population
controls carrying risk factors that may contribute to the develop-
ment of strokeat older ages could have further reduced the power of
the replication study. We estimate that our combined study had
90% power (significance level=0.0005, corrected for 147 tagging
SNPs) to detect single SNPs with MAF 0.2 with ORs of 1.5 (Table
S5). The lack of significant association excludes the presence of
common SNPs in the homocysteine metabolic pathways with effect
sizes of this magnitude or greater on stroke risk.
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number of total risk alleles was seen in the combined initial and
replication samples. This result appears to suggest the 3 variants
might each have small to moderate genetic effects that jointly
contributed to the association of total number of risk alleles with
ischemic stroke risk. This further highlights the importance of joint
association analysis of the cumulative effect from multiple variants
in detecting small to moderate genetic effects. While the effect size
of each positive gene association was weak, the overall contribu-
tion of genetic factors from homocysteine metabolic pathway to
ischemic stroke risk is likely to be relatively large, with a 5.43-fold
different in stroke risk between individuals carrying 5 risk alleles
and those carrying 0 or 1 risk alleles. This could also explain the
finding that apart from MTHFR C677T which has a relatively
stronger genetic effect, most of the associations among other
investigated candidate genes involved in homocysteine metabolism
could not be consistently replicated[20].
We postulate that these genetic risk variants might affect
ischemic stroke risk by jointly modulating homocysteine levels, but
further study will be needed to prove this hypothesis. Interestingly,
genetic association evidence observed in this study is concentrated
in genes that are involved in regulating either folate cycling
(SHMT1 and MTRR) or transportation of vitamin B12 (TCN2)
(Figure 1), suggesting the importance of cellular availability of folate
and vitamin B12 in influencing ischemic stroke risk. Plasma
homocysteine levels are inversely related to plasma concentrations
of folate and vitamin B12 as well as to the intake of these
vitamins[21]. Recently, vitamin supplements have received much
attention as a therapeutic strategy for vascular diseases although the
beneficial effects of lowering plasma homocysteine level by vitamins
on the risk ofischemic strokehavenotyetbeen established[22]. Our
studysuggested thatdeficiencyofboth folateandvitamin B12 levels,
caused by a combination of genetic variations at SHMT1, MTRR
and TCN2, may jointly increase ischemic stroke risk. Unfortunately,
lack of data on the levels of homocysteine, folate and vitamin B12 in
our study subjects limited further investigation of the effect of these
genetic variants on ischemic stroke, which could otherwise be
further established as supporting evidence for the effect of these
variants on the biomarkers.
In conclusion, we have completed a comprehensive genetic
association study of the homocysteine metabolic pathway in
subjects of Chinese ethnicity. Although none of the studied single
variants or haplotypes from the homocysteine metabolic pathway
is significantly associated with ischemic stroke risk, our results
suggest that the joint effect of several small to moderate risk
variants could confer an increase in ischemic stroke risk. We
propose that the genetic etiology of ischemic stroke is likely to be
complex with many loci modulating homocysteine metabolism
and each conferring a small to moderate risk. Further work,
such as validation in larger sample sets, is necessary to confirm
our findings and to explore the joint effects of additional risk
variants.
Table 1. Baseline Characteristics of Control Subjects and Ischemic Stroke Patients.
Candidate Gene Study Replication Study
Characteristics Control(n=354) Ischemic Stroke(n=360) P Control(n=420) Ischemic Stroke(n=420) P
Gender, male, n(%) 161(45.5%) 232(64.4%) ,0.0001 284(67.6%) 292(69.5%) 0.5520
Smokers, n(%) 67(19.0%) 104(28.9%) 0.0021 112(26.7%) 163(38.8%) ,0.0001
Hypertension, n(%) 174(49.3%) 264(73.3%) ,0.0001 194(46.2%) 306(72.9%) ,0.0001
Diabetes, n(%) 72(20.3%) 117(32.5%) ,0.0001 13(3.1%) 172(41.0%) ,0.0001
Hyperlipidemia, n(%) 159(45.4%) 170(47.2%) 0.5103 106(25.2%) 249(59.3%) ,0.0001
Mean Age, years 6SD 59.569.9 64.4611.7 ,0.0001 53.669.2 55.7369.3 0.0013
doi:10.1371/journal.pone.0024757.t001
Table 2. Characteristics of Significant SNPs and Their Association with Ischemic Stroke Risk under Additive Model.
Initial Study Replication Study Combined Analysis
dbSNP ID Gene Alleles
a MAF
b PO R
c TagSNP MAF
b PO R
c MAF
b PO R
c
(95% CI) (95% CI) (95% CI)
rs16879248 MTRR T/C 0.25:
0.19
0.01 0.67
(0.50-0.89)
rs16879259
d 0.19:
0.17
0.29 0.85
(0.63-1.15)
0.22:
0.18
0.004 0.75
(0.61-0.91)
rs11868708 SHMT1 T/C 0.30:
0.36
0 1.46
(1.15-1.86)
rs9909104
e 0.31:
0.34
0.62 1.06
(0.84-1.35)
0.31:
0.35
0.01 1.24
(1.05-1.46)
rs11703570 TCN2 T/A 0.18:
0.22
0.01 1.51
(1.12-2.02)
rs2301955
f 0.18:
0.19
0.36 1.15
(0.85-1.56)
0.18:
0.20
0.018 1.28
(1.04-1.57)
aMajor alleles given first, minor alleles second.
bCase:Control.
cAdjusted risk factors: gender, age, hypertension, diabetes, hyperlipidemia, smoking.
dperfectly correlated with rs16879248 (r
2=1); alleles:T/C.
eperfectly correlated with rs11868708 (r
2=1); alleles:T/C.
fperfectly correlated with rs11703570 (r
2=1); alleles:C/T.
doi:10.1371/journal.pone.0024757.t002
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Ethics Statement
All participants agreed to provide blood samples and written
informed consent for the study. The study was approved by the
Singapore General Hospital Ethics Committee and performed in
observance of the local institutional guidelines.
Study Subjects
The initial study recruited 384 stroke patients and 362 non-
stroke controls 40 to 85 years of age of Singaporean Chinese
ethnicity. All the cases of ischemic stroke were patients admitted to
the Singapore General Hospital (SGH) Stroke Programme.
Clinical diagnosis and classification of ischemic stroke was
confirmed in all patients through the use of brain computerized
tomography (CT) or magnetic resonance imaging (MRI). CT or
MRI was performed within 48 hours of admission and the patients
were systemically evaluated to rigorously determine stroke
phenotype and vascular risk factors (hypertension, diabetes,
hyperlipidemia and smoking). Demographic (age, gender, and
ethnicity) information was also obtained from all the patients.
Controls were healthy volunteers from the Singapore population
who agreed to provide their demographic, health (weight, height,
physical activity) and vascular risk factor information for the study.
Stroke was excluded on the basis of family history and a medical
examination.
For both cases and controls: hypertension was defined as
having a resting blood pressure $ 140/90 mmHg, or treatment
with anti-hypertensive medications; subjects with diabetes were
those having fasting hyperglycemia of $ 7.0 mmol/L, or treat-
ment with insulin or oral hypoglycemic medications; hyperlipide-
mia was defined as having a fasting total cholesterol level of $
6.2 mmol/L or treatment with cholesterol lowering medications;
smoking was defined as those who previously smoked or those who
currently smoked at least 1 cigarette per day.
In the validation study, an additional 708 new stroke samples
from the SGH Stroke Programme were recruited. Clinical
diagnosis, ischemic stroke classification and demographic infor-
mation were obtained as described above in the initial study. 903
stroke-free controls were recruited as part of the Singapore
Prospective Study Program (SP2) which consists of individuals
from 2 previous cross sectional studies, the 1992 National Health
Table 3. Haplotype Frequencies Distributions of Significant Haplotype Blocks among Cases and Controls.
Haplotype Candidate Gene Study Replication Study
SNPs Allele
g Freq Chi Sq PP
h SNPs Allele
g Freq Chi Sq PP
h
Case Control Case Control
SHMT1-CCG rs2273028 C/T 0.364 0.299 6.69 9.71x10
-3 0.78 rs2273028 C/T 0.339 0.312 1.434 0.23 0.96
rs11868708 T/C rs9909104
i T/C
rs2273026 G/A rs2273026 G/A
TCN2-GA rs5749131 A/G 0.042 0.085 11.12 8.54x10
-4 0.13 rs5749131 A/G 0.063 0.06 0.094 0.76 1
rs11703570 A/T rs2301955
j C/T
gMajor alleles given first, minor alleles second.
h1000 permutations performed.
ir
2=1 with rs11868708.
jr
2=1 with rs11703570.
doi:10.1371/journal.pone.0024757.t003
Table 4. Cumulative Effect of Risk Alleles on Ischemic Stroke Risk.
Initial Study Study Replication Study Combined Analysis
No of Risk
Allele
k
Ctrl:Case
(Number) OR
l P
m P Trend
n
Ctrl:Case
(Number) OR
l P
m P Trend
n
Ctrl:Case
(Number) OR
l P
m P Trend
n
0 or 1 63:32 1.00 - 2.0x10
-7 54:38 1.00 - 0.111 117:70 1.00 - 1.20x10
-
6
2 122:111 1.84
(1.07-3.15)
0.027 150:142 1.81
(0.98-3.32)
0.056 272:253 1.77
(1.21-2.60)
0.004
3 120:134 2.40
(1.41-4.08)
0.001 139:155 2.15
(1.18-3.94)
0.013 259:289 2.19
(1.50-3.21)
5.6x10
-5
4 44:66 3.58
(1.93-6.67)
5.6x10
-5 64:65 1.49
(0.75-2.95)
0.257 108:131 2.23
(1.44-3.46)
3.2x10
-4
5 6:17 13.5
(3.94-46.30)
3.5x10
-5 13:20 3.16
(1.16-8.60)
0.025 19:37 5.43
(2.68-11.00)
2.7x10
-6
kRisk alleles are rs16879248:T or rs16879259:T, rs11868708:C or rs9909104:C, rs11703570:A or rs2301955:T.
lAdjusted risk factors: gender, age, hypertension, diabetes, hyperlipidemia, smoking.
mSignificance by comparing to the base group carrying 0 or 1 risk allele.
nP value calculated by Cochran-Armitage Trends Test from the adjusted ORs.
doi:10.1371/journal.pone.0024757.t004
Homocysteine Metabolism Genes & Ischemic Stroke
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e24757Survey and the 1998 National Health survey, each representing a
random sample of the Singapore population, were re-contacted
between 2004 and 2007 [23–24]. Subjects who were successfully
re-contacted and gave informed consent answered a questionnaire
and attended a clinic examination. Fasting blood glucose was
measured for all participants. We observed a significant difference
in mean age of 708 cases (61.6611.7 years) and 903 controls
(46.5610.2 years). Hence, cases and controls were matched with
age and 420 case-control pairs were included in the analysis.
Samples analyzed in the validation study are independent from the
initial samples.
Table 1 summarizes the characteristics of stroke patients and
control subjects in each study. The cases and controls of both the
initial and validation cohorts were significantly different in the
prevalence of smokers, hypertension and diabetes; to adjust for
these differences, we entered these non-genetic factors as
covariates in a logistic regression test for association.
SNP Selection and Genotyping
25 candidate genes known to be involved in homocysteine
metabolic pathway (Figure 1, Table S2) were selected for the present
study. The selection of the SNPs was done by using the SNP
information from the International HapMap project (Phase I data)
[25] and the dbSNP database (Build 124) to produce an evenly
distributed set of SNPs for each gene. In the initial study, 417
SNPs from the 25 candidate genes were selected for genotyping
analysis using the MassArray system from Sequenom (San Diego,
USA) and the GoldenGate Assay from Illumina (San Diego, USA).
After quality control filtering (criteria: MAF.0.03, call rate.0.9,
HWE P.0.05), the final dataset for association analysis contains
the genotyping results of 285 SNPs in 714 samples. In the
replication study, 8 SNPs which show significant association in the
SNP-based and haplotype analysis were selected and genotyped
using MassArray system from Sequenom (San Diego, USA) (Table
S3). More information on the procedure of SNP selection is
provided in the Text S1.
Statistical Analyses
All statistical analyses were performed using STATA 8.0
(StataCorp, TX: College Station), Haploview (version 4.0) and R
program (version 2.2.1) [26–27]. To reduce the redundancy of
SNPs in association analysis and thus the number of association
tests, 147 tagging SNPs were identified from the 285 SNPs by
using Paul de Bakker’ Tagger tag SNP selection algorithm
implemented in Haploview and an r
2 cut-off of 0.8[26].
Association analysis was then performed on the tagging SNPs
using the Cochrane-Armitage trend test. Genetic association was
expressed as odds ratios (OR) of the rarer allele versus the
common allele for having the disease phenotype, and the
significance of association was tested using a logistic regression
analysis adjusting for vascular risk factors, age and gender.
Haplotype analysis was performed within the regions showing
strong linkage disequilibrium (LD). Haplotype phase and popu-
lation frequency were inferred and estimated from genotypes using
the Expectation-Maximization (EM) algorithm implemented in
Haploview, and 35 LD blocks within 19 genes were identified
using the Confidence Intervals method[28-29]. Haplotype associ-
ation analysis was then performed for each common haplotype
Figure 1. Homocysteine Metabolic Pathways. For gene names, refer to Table S2.(Figure adapted from Souto JC, Blanco-Vaca F, Soria JM, Buil A,
Almasy L, et al. (2005) A genomewide exploration suggests a new candidate gene at chromosome 11q23 as the major determinant of plasma
homocysteine levels: results from the GAIT project. Am J Hum Genet 76: 925-933.)
doi:10.1371/journal.pone.0024757.g001
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types showing suggestive evidence (P,0.05) by Haploview
analysis, PHASE (v2.1) was used to reconstruct the haplotypes
from the genotypes[30–31]. In order to account for the multiple
SNPs and haplotypes tested, a permutation procedure (imple-
mented in the Haploview) was used to obtain the corrected P value
of haplotype association.
To assess cumulative effect of multiple variants, a joint
association analysis of the SNPs showing suggestive evidence
(P,0.05) in single SNP association testing was performed. The
total number of risk alleles of the 3 SNPs in each individual was
counted in each individual, as done in a recent study on prostate
cancer[32]. Given the small number of individuals carrying none
of the risk alleles, ORs of individuals carrying 2,3,4 and 5 risk
alleles over the ones carrying none or 1 risk allele for developing
ischemic stroke were evaluated using logistic regression analysis
with adjustment for the aforementioned risk factors. To correct for
model selection bias of the joint analysis, 5000 permutations were
performed to assess significance of the joint effect. Permutation
was done by shuffling the phenotype status in the 714 samples. In
each permutation, SNPs with suggestive evidence of association
(adjusted P,0.05) from the trend analysis were identified first, and
significance (P value) of the joint effect of suggested SNPs was then
evaluated in the same way using multi-variable logistic regression
analysis. Finally, P values from 5000 permutations were used to
determine significance or exact P value of the joint effect of the 3
risk variants identified in this study.
Pair-wise interaction among SNPs was also investigated by
adding an interaction term into the logistic regression analysis. An
interaction is found to be significant if likelihood-ratio test P value
is less than 0.05. All power estimations were computed using
QUANTO (v1.2) [33–34].
SNP-based, haplotype and joint association analysis for the 8
selected SNPs in replication samples were carried out as described
above.
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